Products Categories
| CAS No.: | 51753-57-2 |
|---|---|
| Name: | 7-Bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-Benzodiazepin-2-one |
| Article Data: | 3 |
| Molecular Structure: | |
|
|
|
| Formula: | C15H10BrClN2O |
| Molecular Weight: | 349.614 |
| Synonyms: | 7-Bromo-5-(2-chlorophenyl)-1,3-dihydrobenzo[e]-1,4-diazepin-2-one;BD 98;Fenazepam; |
| EINECS: | 200-835-2 |
| Density: | 1.61 g/cm3 |
| Melting Point: | 225-230oC |
| Boiling Point: | 493 °C at 760 mmHg |
| Flash Point: | 251.9 °C |
| Solubility: | soluble in water and ether, micro-soluble in 95% ethanol, dissolved in chloroform. 0.1 grams of samples dissolved in 5 ml chloroform |
| Appearance: | White or off-white crystalline powder |
| Hazard Symbols: | F,Xn |
| Risk Codes: | 11-20/21/22-36 |
| Safety: | 16-36/37 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 548773-13-32-amino-4,6-dimethylpyrimidine-5-carboxylic acid
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Chemistry
IUPAC Name: 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
Synonyms of Phenazepam (CAS NO.51753-57-2): 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-bromo-5-(2-chlorophenyl)- ; Fenazepam ; Phenazepam
CAS NO: 51753-57-2
Molecular Formula: C15H10BrClN2O
Molecular Weight: 349.609
Molecular Structure: 
H bond acceptors: 3
H bond donors: 1
Freely Rotating Bonds: 1
Polar Surface Area: 32.67 Å2
Index of Refraction: 1.691
Molar Refractivity: 83.14 cm3
Molar Volume: 217.1 cm3
Surface Tension: 53.2 dyne/cm
Density: 1.61 g/cm3
Flash Point: 251.9 °C
Enthalpy of Vaporization: 76 kJ/mol
Boiling Point: 493 °C at 760 mmHg
Vapour Pressure: 7.32E-10 mmHg at 25°C
SMILES: Clc3ccccc3C/2=N/CC(=O)Nc1c\2cc(Br)cc1
InChI: InChI=1/C15H10BrClN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)
InChIKey: CGMJQQJSWIRRRL-UHFFFAOYAF
Std. InChI: InChI=1S/C15H10BrClN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)
Std. InChIKey: CGMJQQJSWIRRRL-UHFFFAOYSA-N
Product Categories of Phenazepam (CAS NO.51753-57-2): Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Uses
Phenazepam is a benzodiazepine drug, which is used in the treatment of neurological disorders such as epilepsy, alcohol withdrawal syndrome and insomnia. Besides, Phenazepam can be still used as a premedication before surgery as it enhance the effects of anesthetics and reduces anxiety.
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intraperitoneal | 620mg/kg (620mg/kg) | Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 13(10), Pg. 108, 1979. | |
| mouse | LD50 | oral | 2400mg/kg (2400mg/kg) | Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 13(10), Pg. 108, 1979. | |
| rat | LD50 | intraperitoneal | 720mg/kg (720mg/kg) | Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 13(10), Pg. 108, 1979. |
Safety Profile
Moderately toxic by ingestion and intraperitoneal routes. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of Cl−, Br−, and NOx.
Specification
Side effects of Phenazepam (CAS NO.51753-57-2):
Phenazepam cause such side effects as follows: dizziness, loss of coordination and drowsiness, along with anterograde amnesia which can be quite pronounced at high doses. As with other benzodiazepines, in case of abrupt discontinuation following prolonged use, severe withdrawal symptoms may occur, such as restlessness, anxiety, insomnia and convulsions.